4.60
Scpharmaceuticals Inc Borsa (SCPH) Ultime notizie
Using R and stats models for scPharmaceuticals Inc. forecastingChart Signals & Free Accurate Trade Setup Notifications - Newser
Why scPharmaceuticals Inc. stock attracts strong analyst attentionJuly 2025 Sector Moves & Real-Time Volume Surge Alerts - Newser
What makes scPharmaceuticals Inc. stock price move sharplyMarket Sentiment Summary & AI Optimized Trading Strategy Guides - Newser
What data driven models say about scPharmaceuticals Inc.’s futureJuly 2025 Big Picture & Reliable Entry Point Trade Alerts - Newser
Quantitative breakdown of scPharmaceuticals Inc. recent moveProduct Launch & Fast Momentum Entry Tips - Newser
Building trade automation scripts for scPharmaceuticals Inc.Portfolio Growth Summary & Technical Buy Zone Confirmation - Newser
scPharmaceuticals secures notice of allowances of multiple US patent applications covering SCP-111 - MSN
Can a trend reversal in scPharmaceuticals Inc. lead to recoveryEarnings Summary Report & AI Enhanced Trading Alerts - Newser
Sentiment analysis tools applied to scPharmaceuticals Inc.Weekly Risk Summary & Daily Oversold Bounce Ideas - Newser
Published on: 2025-08-15 05:16:39 - sundaytimes.kr
Sector Update: Health Care - MarketScreener
ScPharmaceuticals Inc. shares rise 1.05% intraday after receiving five patent allowances for SCP-111 formulation. - AInvest
scPharmaceuticals receives five patent allowances for furosemide formulation By Investing.com - Investing.com Nigeria
scPharmaceuticals Strengthens IP Portfolio with 5 New Patents for Innovative Heart Failure Treatment - Stock Titan
Is scPharmaceuticals Inc. forming a reversal pattern2025 Market Sentiment & AI Driven Stock Movement Reports - Newser
SCPharmaceuticals to Meet with Craig-Hallum on August 19 - AInvest
What’s the recovery path for long term holders of scPharmaceuticals Inc.Daily Trade Setup Forecast with Confidence - Newser
scPharmaceuticals Inc. (NASDAQ:SCPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Does scPharmaceuticals Inc. qualify in momentum factor screeningAI Volatility Forecast and Risk Monitor - Newser
Strategies to average down on scPharmaceuticals Inc.Free Swing Setup With Technical Confirmation - Newser
scPharmaceuticals Inc. stock trendline breakdownFree Swing Setup With Technical Confirmation - Newser
Comparing scPharmaceuticals Inc. in custom built stock radarsFree Daily Smart Money Movement Monitor - Newser
Chart based analysis of scPharmaceuticals Inc. trendsLow Exposure Strategy with Sector Analysis - Newser
What earnings revisions data tells us about scPharmaceuticals Inc.Free Watchlist for Smart Swing Trading - Newser
Using data tools to time your scPharmaceuticals Inc. exitFree Watchlist for Low Risk High Return - Newser
How to monitor scPharmaceuticals Inc. with trend dashboardsEntry Optimization Guide with Volume Analysis - Newser
Using Bollinger Bands to evaluate scPharmaceuticals Inc.Real-Time Entry Forecast with Accuracy Metrics - Newser
Wall Street Zen Upgrades scPharmaceuticals (NASDAQ:SCPH) to “Hold” - Defense World
Analyzing scPharmaceuticals Inc. with multi timeframe chartsShort-Term AI-Based Stock Price Forecast - Newser
What Fibonacci levels say about scPharmaceuticals Inc. reboundVolume Confirmed Setup with Entry Confidence - Newser
How scPharmaceuticals Inc. stock performs during market volatility [Gold Moves]Long Hold Capital Preservation Plans - Newser
What institutional flow reveals about scPharmaceuticals Inc.Free Market Surge Signal for Swing Traders - Newser
Identifying reversal signals in scPharmaceuticals Inc.Long Term Stock Growth Plan Suggestions - Newser
Analyzing net buyer seller activity in scPharmaceuticals Inc.AI-Powered Stock Trend Movement Analysis - Newser
scPharmaceuticals Inc. Stock Performance After Earnings: Historical InsightsFree Fast Entry High Potential Stock Alerts - Newser
ScPharmaceuticals anticipates meaningful Q3 nephrology contribution as FUROSCIX shipments rise 45% in Q2 2025 - MSN
Strong Financial Performance and Strategic Initiatives Justify Buy Rating for scPharmaceuticals - TipRanks
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):